169P Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

Autor:	Xiaobin Ma, Fei Wu, Shuqun Zhang, Hai-Tao Guan, Weili Min, Y.X. Li, Xi Chen, Xia Li, Ming Liu, Dingxin Liu, Huafeng Kang, Cong Feng, Yinbin Zhang, Q. She, Yan Diao
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Hematology Single Center Clinical study Neoadjuvant treatment Internal medicine medicine Stage (cooking) business Triple-negative breast cancer
Zdroj:	Annals of Oncology. 32:S433
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.450
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::59157e1eb7706bb64e76e7675d52762e https://doi.org/10.1016/j.annonc.2021.08.450 Zobrazit plný text záznamu